193 related articles for article (PubMed ID: 37972575)
1. Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.
Tokizaki S; Podyma-Inoue KA; Matsumoto T; Takahashi K; Kobayashi M; Ibi H; Uchida S; Iwabuchi S; Harada H; Hashimoto S; Miyazono K; Shirouzu M; Watabe T
Cancer Sci; 2024 Jan; 115(1):211-226. PubMed ID: 37972575
[TBL] [Abstract][Full Text] [Related]
2. Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer.
Takahashi K; Akatsu Y; Podyma-Inoue KA; Matsumoto T; Takahashi H; Yoshimatsu Y; Koinuma D; Shirouzu M; Miyazono K; Watabe T
J Biol Chem; 2020 Sep; 295(36):12559-12572. PubMed ID: 32631954
[TBL] [Abstract][Full Text] [Related]
3. Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor.
Kodama S; Podyma-Inoue KΑ; Uchihashi T; Kurioka K; Takahashi H; Sugauchi A; Takahashi K; Inubushi T; Kogo M; Tanaka S; Watabe T
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34296292
[TBL] [Abstract][Full Text] [Related]
4. Ovarian transforming growth factor-beta (TGF-beta) receptors: in-vitro effects of follicle stimulating hormone, epidermal growth factor and TGF-beta on receptor expression in human preantral follicles.
Roy SK; Kole AR
Mol Hum Reprod; 1998 Mar; 4(3):207-14. PubMed ID: 9570266
[TBL] [Abstract][Full Text] [Related]
5. Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II.
Song K; Krebs TL; Danielpour D
J Biol Chem; 2006 Mar; 281(12):7765-74. PubMed ID: 16428382
[TBL] [Abstract][Full Text] [Related]
6. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors.
Liu C; Li J; Xiang X; Guo L; Tu K; Liu Q; Shah VH; Kang N
Am J Physiol Gastrointest Liver Physiol; 2014 Oct; 307(7):G749-59. PubMed ID: 25169976
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells.
Wells RG; Gilboa L; Sun Y; Liu X; Henis YI; Lodish HF
J Biol Chem; 1999 Feb; 274(9):5716-22. PubMed ID: 10026191
[TBL] [Abstract][Full Text] [Related]
8. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
9. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.
Rechtman MM; Nakaryakov A; Shapira KE; Ehrlich M; Henis YI
J Biol Chem; 2009 Mar; 284(12):7843-52. PubMed ID: 19147499
[TBL] [Abstract][Full Text] [Related]
10. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
[TBL] [Abstract][Full Text] [Related]
11. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II.
Guerrero-Esteo M; Sanchez-Elsner T; Letamendia A; Bernabeu C
J Biol Chem; 2002 Aug; 277(32):29197-209. PubMed ID: 12015308
[TBL] [Abstract][Full Text] [Related]
12. A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation.
Zhu HJ; Sizeland AM
J Biol Chem; 1999 Apr; 274(17):11773-81. PubMed ID: 10206994
[TBL] [Abstract][Full Text] [Related]
13. The type II TGF-β receptor phosphorylates Tyr
Yakymovych I; Yakymovych M; Hamidi A; Landström M; Heldin CH
Sci Signal; 2022 Nov; 15(760):eabp9521. PubMed ID: 36378749
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Mincione G; Di Marcantonio MC; Artese L; Vianale G; Piccirelli A; Piccirilli M; Perrotti V; Rubini C; Piattelli A; Muraro R
Int J Oncol; 2008 Feb; 32(2):323-31. PubMed ID: 18202754
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta (TGF-beta) type I and type II receptors are both required for TGF-beta-mediated extracellular matrix production in lung fibroblasts.
Zhao Y
Mol Cell Endocrinol; 1999 Apr; 150(1-2):91-7. PubMed ID: 10411303
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells.
Kim SI; Kwak JH; Na HJ; Kim JK; Ding Y; Choi ME
J Biol Chem; 2009 Aug; 284(33):22285-22296. PubMed ID: 19556242
[TBL] [Abstract][Full Text] [Related]
18. Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule.
Qian SW; Burmester JK; Tsang ML; Weatherbee JA; Hinck AP; Ohlsen DJ; Sporn MB; Roberts AB
J Biol Chem; 1996 Nov; 271(48):30656-62. PubMed ID: 8940041
[TBL] [Abstract][Full Text] [Related]
19. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction.
Luo K; Lodish HF
EMBO J; 1996 Sep; 15(17):4485-96. PubMed ID: 8887540
[TBL] [Abstract][Full Text] [Related]
20. Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.
Tian H; Liu J; Chen J; Gatza ML; Blobe GC
Oncogene; 2015 Nov; 34(45):5635-47. PubMed ID: 25823021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
